Holgate was educated at The King's School in Macclesfield until 1965, when he joined Charing Cross Hospital Medical School, London (now incorporated into Imperial College London) where he received a BSc and MB BS. After completing postgraduate medical training in London at the National Hospital for Nervous Diseases and the Royal Brompton Hospital, he moved to Salisbury and Southampton where he completed his specialist higher medical training in general and respiratory medicine.
While a Clinical Lecturer at the University of Southampton, he researched the link between asthma death and over-use of beta-adrenergic bronchodilator inhalers. In 1978, Holgate received a Doctor of Medicine (MD) degree from the University of London.[4][5]
In 1980, Holgate completed a two year post doctoral fellowship with K. Frank Austen at the Robert Brigham Hospital and Harvard University, Boston provided by the Dorothy Temple Cross MRC endowment and the Wellcome Trust.[citation needed]
In 1980, Holgate began work at the University of Southampton researching the causes of human asthma and its treatment. After establishing the role that mast cells and other effector cells play in triggering the acute allergic inflammatory response in asthma, he examined the mechanisms of asthma chronicity and variability.
In 2002, Holgate collaborated with Donna Davies and Genome Therapeutics Corporation in Waltham, Mass, USA to identify the first novel asthma susceptibility gene of ADAM33 that encodes a metalloprotease linked to airway hyperresponsiveness and remodelling. This originated from the theory that in severe asthma, the airways behaved like a chronic wound with impaired epithelial repair and underlying tissue remodelling involving the deposition of new matrix, mucous metaplasia and proliferation of smooth muscle.
Holgate and his research group demonstrated the causal link between exacerbations in the autumn and winter months and respiratory virus infections. This led to the subsequent discovery that epithelial cells from those with moderate-severe asthma were deficient in their ability to generate an innate interferon beta response when infected by human rhinoviruses.
In 2003 Holgate, Donna Davies and Ratko Djukanovic [Wikidata] used this patented information to create the University spin-off company Synairgen to explore the potential therapeutic benefits of inhaled interferon beta in attenuating virus-induced exacerbations of asthma and COPD. Synairgen completed a Phase II placebo-controlled trial to treat COVID-19.[6][7][8]
^Holgate, Stephen; Agusti, Alvar; Strieter, Robert M.; Anderson, Gary P.; Fogel, Robert; Bel, Elisabeth; Martin, Thomas R.; Reiss, Theodore F. (2015). "Drug development for airway diseases: looking forward". Nature Reviews Drug Discovery. 14 (6): 367–368. doi:10.1038/nrd4645. ISSN1474-1776. PMID26000726. S2CID8539798.
